~~<i id='262B780F54'><strike id='262B780F54'><tt id='262B780F54'><pre id='262B780F54'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

knowledge

author：comprehensive 2025-08-12 11:29:34 - browse：67

In a dark grey suit and light blue button-down shirt, Bill Sibold, CEO of Madrigal Pharmaceuticals, smiles— coverage from STAT — Madrigal CEO Bill Sibold says the company is "interested in the patients who are most in need." Madrigal Pharmaceuticals

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week.

The pill, called resmetirom, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH and previously called NASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Scientists inch closer to single

knowledge

focus

explore

knowledge

hotspot

focus

MikeReddyforSTATSimonMatthewsmadethreetripsthisspringtotheemergencyroomofhislocalhospitalinEastbourn

WSS

Ascension's ugly legal battle over care for poor patients in Texas

Physician groups backed by private equity giant lobby on mergers

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Breakthrough Alzheimer’s drugs are inaccessible in rural states

‘Oppenheimer’ and the risks of AI in health care

Merck to acquire Harpoon Therapeutics for $680 million

entertainment

knowledge

knowledge

Supreme Court strikes down use of affirmative action

At JPM 2024, hospital systems pitch financial strength to investors

In Memoriam: Notable people who died in 2023

What the airline industry can learn from medicine

Peter Hotez and the public health issue of online harassment

Stories you might have missed in 2023: health, science, medicine

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Apple is now the first public company to be valued at $3 trillion

Medicare Advantage overpayments discussion gets experts fired up

focus

Fauci's latest grilling in Congress: 9 hours, behind closed doors

STAT Virtual Event: JPM Recap, Live!

Mega Millions pot grows to $1.25 billion after no winner

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Physician assistants need a new name. Here's what it should be

explore

knowledge

hotspot

focus